HPV Testing and PAP Test Market - By Test Type (Human Papillomavirus Testing, Co-testing, Papanicolaou Test), By Technology, (Polymerase Chain Reaction (PCR), Liquid-based Cytology, Hybrid Capture, Immunodiagnostics), By End-use (Hospitals, Diagnostic Cen

HPV Testing and PAP Test Market - By Test Type (Human Papillomavirus Testing, Co-testing, Papanicolaou Test), By Technology, (Polymerase Chain Reaction (PCR), Liquid-based Cytology, Hybrid Capture, Immunodiagnostics), By End-use (Hospitals, Diagnostic Centers) & forecast, 2023 - 2032

Global HPV Testing and PAP Test Market size will expand significantly through 2032. Recent advancements in HPV and PAP tests will create notable growth opportunities for the industry. Advances in image analysis and AI have led to the development of computer-assisted systems for Pap test interpretation. These systems can aid pathologists by highlighting abnormal cells, potentially improving the accuracy and efficiency of the screening process.

The overall global HPV testing and PAP test market is divided based on test, technology, end-use, and region.

Based on the test, industry share from the co-testing segment will grow at over 16% CAGR from 2023 to 2032. The rising prevalence of cervical cancer and HPV-related sexually transmitted diseases has increased the demand for co-testing. As per the American Cancer Society, in 2023, around 13,960 new invasive cervical cancer cases will be diagnosed in the U.S. alone. Co-testing provides higher sensitivity in detecting cervical abnormalities compared to either test alone. The combination of HPV testing and Pap testing improves the detection of high-grade precancerous lesions and early-stage cervical cancer.

Based on the technology, industry value from the polymerase chain reaction (PCR) segment will register lucrative gains through 2032. High sensitivity and specificity of PCR tests allow for the accurate detection and identification of HPV DNA, favoring segment growth. Moreover, PCR testing can identify the presence of persistent HPV infections, which are considered to have a higher risk of developing cervical cancer. Growing awareness about the early detection of HPV infection will further contribute to segment growth.

Based on the end use, industry value from the diagnostic centers segment will witness substantial gains through 2032. Growing preference towards diagnostic laboratories owing to the availability of advanced technologies and cost-effective treatment in these facilities is leading to segment growth. These centers also offer accurate and early disease diagnosis, which increases patient footfall. Surging number of diagnostic centers will further create lucrative opportunities for segment growth.

From the regional perspective, the Asia Pacific HPV testing and PAP test market size will reach over USD 2.5 billion by 2032. Surging female population base’s susceptibility to cervical cancer has increased the need for HPV and PAP testing in the region. Moreover, regional expansion can also be attributed to expanding healthcare infrastructure, in line with favorable regulatory scenarios for modalities. As per IBEF, India’s medical device market will reach USD 50 billion by 2025.